Apixaban tablet

Abstract

The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to an apixaban tablet. The apixaban tablet contains apixaban, hydroxy propyl cellulose and fumed silica. A preparation method of the apixaban tablet comprises the following steps: dissolving apixaban and hydroxy propyl cellulose in diethylene glycol monoethyl ether, adding with fumed silica for adsorption, then uniformly mixing with pharmaceutically acceptable auxiliary materials, and carrying out pressing by adopting a direct tableting technology. Compared with the prior art, the apixaban tablet has the advantages that the medicine dissolution speed is high, the process is simple, a surfactant does not need to be added, and the micronization treatment is not needed. The acceleration test result shows that the prepared apixaban tablet is good in stability.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, in particular to an apixaban tablet. Background technique [0002] Apixaban is a novel oral direct factor Xa inhibitor that activates coagulation factor Xa (whose main practical role is to generate thrombin through restricted proteolysis of prothrombin) in the final common pathway of coagulation in connection with endogenous The important position of sex and exogenous activation mechanism. Thrombin (the final serine protease in the pathway to produce a fibrin clot from its precursor) is produced by the formation of the prothrombin enzyme complex (coagulation factor Xa, coagulation factor V, Ca 2+ and phospholipids) are amplified. Since one factor Xa molecule was calculated to generate 138 thrombin-inhibiting molecules, factor Xa may be more effective in interrupting the coagulation system than inactivation of thrombin. Thus, factor Xa inhibitors are a class of compounds tha...

AI Technical Summary

Problems solved by technology

[0004] Foreign countries adopt the dry granulation process after micronization of raw materials, although it has been improved to a certain extent, but the dry granulation process is complicated, the dust production is large, and the particle size is not uniform, and the surface finish of the pressed tablet is poor.

[0005] CN102908324A discloses an apixaban tablet, comprising apixaban, a water-soluble carrier material, a filler, a disintegrant, and a glidant, which improves the disadvantages of poor in vitro dissolution and low bioavailability of apixaban

However, due to the low melting point of polyethylene glycol, there is a problem of easy sticking during production

Images